<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03765736</url>
  </required_header>
  <id_info>
    <org_study_id>ACCRU-GI-1611</org_study_id>
    <secondary_id>NCI-2018-02862</secondary_id>
    <secondary_id>ACCRU-GI-1611</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03765736</nct_id>
  </id_info>
  <brief_title>Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial</brief_title>
  <official_title>COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic and Community Cancer Research United</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial screens patients with colon or rectal cancer that has spread to other places in&#xD;
      the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations&#xD;
      for recommendation to a molecularly assigned therapy. Identifying gene mutations may help&#xD;
      patients enroll onto target companion trials that target these mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To perform blood-based genomic profiling on patients with treatment refractory metastatic&#xD;
      colorectal cancer (CRC) to facilitate accrual to molecularly assigned therapies.&#xD;
&#xD;
      II. To facilitate clinically annotated genomic analyses.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients submit blood samples for genetic testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">November 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who have an actionable genomic profile</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This is defined as a patient who received a trial recommendation per the COLOMATE companion trial recommendation form. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Companion trial enrollment</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>This is defined as a patient who has an actionable genomic profile that enrolls in their recommended companion trial. Will be presented as a point estimate along with a 95% confidence interval (by Wald asymptotic confidence limit).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Metastatic Colon Adenocarcinoma</condition>
  <condition>Metastatic Rectal Adenocarcinoma</condition>
  <condition>Stage III Colon Cancer AJCC v8</condition>
  <condition>Stage III Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIA Colon Cancer AJCC v8</condition>
  <condition>Stage IIIA Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIB Colon Cancer AJCC v8</condition>
  <condition>Stage IIIB Rectal Cancer AJCC v8</condition>
  <condition>Stage IIIC Colon Cancer AJCC v8</condition>
  <condition>Stage IIIC Rectal Cancer AJCC v8</condition>
  <condition>Stage IV Colon Cancer AJCC v8</condition>
  <condition>Stage IV Rectal Cancer AJCC v8</condition>
  <condition>Stage IVA Colon Cancer AJCC v8</condition>
  <condition>Stage IVA Rectal Cancer AJCC v8</condition>
  <condition>Stage IVB Colon Cancer AJCC v8</condition>
  <condition>Stage IVB Rectal Cancer AJCC v8</condition>
  <condition>Stage IVC Colon Cancer AJCC v8</condition>
  <condition>Stage IVC Rectal Cancer AJCC v8</condition>
  <condition>Unresectable Colon Adenocarcinoma</condition>
  <condition>Unresectable Rectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <description>Patients submit blood samples for genetic testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Undergo genetic testing</description>
    <arm_group_label>Screening (genetic testing)</arm_group_label>
    <other_name>genetic analysis</other_name>
    <other_name>Genetic Examination</other_name>
    <other_name>Genetic Test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with adenocarcinoma of the colon or rectum that is metastatic and/ or unresectable&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of adenocarcinoma of the colon or rectum that is metastatic&#xD;
             and/ or unresectable&#xD;
&#xD;
          -  Progression, intolerance, or contraindication to a fluoropyrimidine (e.g., 5-&#xD;
             fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal&#xD;
             antibody (bevacizumab, ziv-aflibercept, or ramucirumab), and an anti-PD-1 monoclonal&#xD;
             antibody (nivolumab or pembrolizumab) if tumor has deficient mismatch repair proteins&#xD;
             (dMMR) or is microsatellite instability-high (MSI-H)&#xD;
&#xD;
          -  For patients with KRAS and NRAS wild-type tumors, progression, intolerance, or&#xD;
             contraindication to an anti-EGFR monoclonal antibody (cetuximab or panitumumab)&#xD;
&#xD;
               -  Note: If tissue is known to be positive for HER2 expression (IHC 3+) or the tumor&#xD;
                  has ERBB2 (HER2) amplification detected by a Clinical Laboratory Improvement Act&#xD;
                  (CLIA)-certified assay, prior treatment with anti-EGFR therapy is not required&#xD;
&#xD;
          -  At least one site of disease that is measurable by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) criteria (version 1.1) that has not been previously irradiated;&#xD;
             if the patient has had previous radiation to the target lesion(s), there must be&#xD;
             evidence of progression since the radiation&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months per estimation of investigator&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2&#xD;
&#xD;
          -  Capable of understanding and complying with the protocol requirements and has signed&#xD;
             the informed consent document&#xD;
&#xD;
          -  Satisfy at least one of the following two conditions:&#xD;
&#xD;
               -  Willing and able to provide blood sample for screening purposes&#xD;
&#xD;
               -  Guardant 360 testing completed =&lt; 60 days prior to registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence within the last 3 years of another malignancy which required systemic&#xD;
             treatment. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix, or&#xD;
             localized prostate cancer with a current PSA of &lt; 1.0mg/dL on 2 successive&#xD;
             evaluations, at least 90 days apart, with the most recent evaluation no more than 4&#xD;
             weeks prior to registration&#xD;
&#xD;
          -  Unable or unwilling to abide by the study protocol or cooperate fully with the&#xD;
             investigator or designee&#xD;
&#xD;
          -  History of solid organ transplantation&#xD;
&#xD;
          -  Pregnant or planning to become pregnant within the next 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H Strickler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referrals Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Tanios S. Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ceonne Kim</last_name>
      <phone>858-822-0201</phone>
      <email>cek008@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Shumei Kato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Rehman</last_name>
      <phone>323-865-0460</phone>
      <email>Rabia.Rehman@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Heinz-Josef Lenz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Kearns</last_name>
      <phone>253-831-3423</phone>
      <email>Karen.Kearns@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Jun Gong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violeta Milic</last_name>
      <phone>202-687-2353</phone>
      <email>Vm524@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin A. Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeremy C. Jones</last_name>
      <email>jones.jeremy1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremy C. Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KJ Lee</last_name>
      <phone>404-778-3173</phone>
      <email>kyungjong.lee@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Christina S. Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Intake Team</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel V. Catenacci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GCC Nursing</last_name>
      <phone>617-632-3000</phone>
      <email>DFCIGCCRNRS@partners.org</email>
    </contact>
    <investigator>
      <last_name>Kimmie Ng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referrals Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Joleen M. Hubbard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7462</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Katrina S. Pedersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Jackson</last_name>
      <phone>732-235-4024</phone>
      <email>jacsoka@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick M. Boland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACCRU Operations</last_name>
      <phone>507-538-7457</phone>
      <email>ACCRU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Cercek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Amara</last_name>
      <phone>919-668-1861</phone>
      <email>Anthony.amara@duke.edu</email>
    </contact>
    <investigator>
      <last_name>John H. Strickler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Derzic</last_name>
      <phone>412-330-6263</phone>
      <email>Karen.derzic@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Gene G. Finley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Intake Team</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Kristen K. Ciombor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ngozi Nwokeji</last_name>
      <phone>713-792-2828</phone>
      <email>nfnwokeji@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Christine Parseghian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Cheeks</last_name>
      <email>karen.cheeks@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Federico A. Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

